CHI’s Small-Molecule Discovery Technologies conference covers lead-generation approaches ranging from well-established fragment-based ligand design to newer medicinal chemistry advances such as covalent chemistry and direct-to-biology (D2B) applications. A focus will be on the technological innovations of the biophysical-based tools enabling small-molecule drug discovery against difficult-to-drug targets such as protein-protein interactions (PPIs). But classic small molecule enzyme-inhibitor discovery stories, reflecting the event’s medicinal chemistry roots, will also be included. The more detailed discovery stories of small molecules advancing against PPI targets will be covered in our companion Targeting Protein-Protein Interactions conference in the second half of Drug Discovery Chemistry. The back-to-back conferences keep you apprised of new biophysical approaches, innovative applications of well-established tools, and small-molecules showing medical promise. All while providing the chance to interact with leaders in the fields of medicinal and biophysical chemistry.